Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • Platform
    • Strategy
    • Progress
    • Publications
  • Pipeline
    • Overview
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Apr 06, 2020 7:30am EDT

Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board

Apr 01, 2020 5:53pm EDT

Sonnet BioTherapeutics Holdings Announces Merger Closing

Feb 28, 2020 9:55am EST

Sonnet BioTherapeutics to Present at the 40th Annual Cowen Health Care Conference

Oct 22, 2019 9:28am EDT

Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate

Oct 10, 2019 4:05pm EDT

Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics

Aug 12, 2019 7:47am EDT

Sonnet BioTherapeutics Announces Acquisition Agreement with Relief Therapeutics Holding SA for Atexakin Alpha (Interleukin-6)

Jul 17, 2018 10:26am EDT

Sonnet BioTherapeutics announces successful completion of Immuno-Oncology Discovery Program and Initiation of CMC Development of Platform Assets

Sep 25, 2017 11:36am EDT

Sonnet Biotherapeutics to present data on bispecific platform candidates at AACR and SITC Annual Meetings

RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    © 2023 Sonnet BioTherapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap